News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Roche Holding AG Seeks to Broaden Use of Cancer Drug MabThera
March 22, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Swiss drugmaker Roche Holding AG (ROG.VX) is looking to broaden the use of its cancer drug MabThera in non-Hodgkin's lymphoma in Europe, underscoring the strength of its position in oncology.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Opinion
The next FDA commissioner must be a champion for gene therapies
June 5, 2026
·
4 min read
·
Erik Paulsen
Regulatory
Stakeholders want Makary’s voucher program paused, call for FDA independence
June 5, 2026
·
3 min read
·
Tristan Manalac
Insights
Rethinking hair loss treatment
June 4, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Policy
FDA taps prior knowledge to expedite cell and gene therapy development
June 3, 2026
·
12 min read
·
BioSpace Editorial Staff
